A BREAKTHROUGH INNOVATION IN ALLOGENEIC CELL THERAPY FOR TISSUE REPAIR
Scarcell Therapeutics is developing an innovative, highly differentiated allogeneic cell therapy platform to address major unmet clinical needs in a variety of indications.
Scarcell Therapeutics' cell therapy platform was designed based on the discovery that human Gingival Fibroblasts (hGF) harvested from gum tissue have unique properties, including a regenerative effect on other tissues, making them particularly safe and effective for therapeutic use in a wide range of clinical applications.
When compared to conventional cell therapy products such as Mesenchymal Stem Cells (MSC), induced Pluripotent Stem cells (iPS), Embryonic Stem cells (ES) and other autologous and allogeneic cells, hGFs have a unique combination of superior therapeutic properties:
• Tissue repair that is both fast and precise
• Powerful and durable anti-inflammatory action
• Allogeneic and therefore non tumorigenic
• Long-lasting therapeutic effect due to increased cell survival
In addition, Scarcell Therapeutics has developed a proprietary production process for its hGF cell therapy that allows high-capacity manufacturing at a fraction of the usual cost. The process is also environmentally friendly as it does not use harmful chemicals for cell culturing and expansion.
Scarcell Therapeutics has chosen to develop its first product for the treatment of osteoarthritis.
Knee Osteoarthritis (OA) is a debilitating disease affecting millions of patients worldwide. Most currently approved products relieve pain and increase joint mobility, thus relieving symptoms. Scarcell Therapeutics’ hGF cell therapy has the potential to not only relieve symptoms, but also to regenerate cartilage in patients suffering from osteoarthritis thereby delaying the need for surgical joint replacement.
Scarcell Therapeutics’ goal is to provide effective, easy to use, affordable cell therapies to meet a wide variety of unmet clinical needs.